CCR2 Antikörper

Produktnummer ABIN2664331

Der Maus Monoklonal Anti-CCR2-Antikörper wurde für ICFC validiert. Er ist geeignet, CCR2 in Proben von Human zu detektieren.

Kurzübersicht für CCR2 Antikörper (ABIN2664331)

Target: CCR2 (Chemokine (C-C Motif) Receptor 2 (CCR2))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CCR2 Antikörper ist unkonjugiert

Applikation: Intracellular Flow Cytometry (ICFC)

Klon: K036C2

Produktdetails anti-CCR2 Antikörper

Aufreinigung: The antibody was purified by affinity chromatography.

Isotyp: IgG2a kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu CCR2

Target: CCR2 (Chemokine (C-C Motif) Receptor 2 (CCR2))

Andere Bezeichnung: CD192

Hintergrund: CCR2 is a chemokine receptor that binds monocyte chemoattractant proteins (MCP-1, 2, 3 and 4). Two spliced variants were initially described for CCR2 (CCR2A and CCR2B). These variants differ in their terminal carboxyl tails. Monocyte adhesion to the arterial endothelium and subsequent migration into the intima are central events in the pathogenesis of atherosclerosis. CCR2 and MCP-1 have been associated to atherosclerotic plaques. MCP-1 is induced by modified-LDL in endothelial cells and may trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Local overexpression of MCP-1 at vessel walls induces infiltration of macrophages and formation of atherosclerotic lesions. Obesity induces an inflammatory state that is implicated in many clinically important complications, including insulin resistance, diabetes, atherosclerosis, and non-alcoholic fatty liver disease. CCR2 influences the development of obesity and associated adipose tissue inflammation.

Pathways: cAMP Metabolic Process, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process